Daniel B. Ravicher
Healthcare, tech, patents, litigation

Expected Decision In Avanir Nuedexta Patent Litigation

Avanir's Main Product Is Nuedexta

Avanir (NASDAQ:AVNR) is a small (~$500M market cap) pharmaceutical company that develops and sells drugs for central nervous system disorders. It has two drugs on the market, Nuedexta and Abreva, and a couple in the pipeline. In the company's most recently reported quarterly results released December 10, Nuedexta, which has a gross margin of 94.3%, accounted for 93% of Avanir's total net revenue. It grossed $91.2 million in revenue for the year, representing more than 100% growth on a year-over-year basis. Nuedexta will become even more important to Avanir this spring, as the company will stop recognizing revenue from its only other approved product, Abreva, when its patent expires in April 2014. Some...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details